Eli Lilly Weight Loss - Search News

Eli Lilly, Novo Nordisk and drug Wegovy

Reuters on MSN · 4d

Eli Lilly plans launch of weight-loss drug in emerging markets by 2026, CFO says

(Reuters) -Eli Lilly plans to launch its blockbuster diabetes and weight-loss drug, Mounjaro, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday.

Investopedia on MSN · 2d

Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss pharmaceutical firm signed an exclusive agreement with Zealand Pharma to produce treatments using Zealand's experimental petrelintide injectable.

USA TODAY on MSN · 9d

Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured

After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight-loss drug Wegovy.

Weight Loss, Food and Drug Administration

The New York Times · 22h

How Much Should Weight Loss Drugs Cost?

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

USA TODAY on MSN · 10d

These discounted versions of popular weight-loss drugs are going away: What to know

Consumers who use telehealth or medical spas to get less expensive, compounded weight loss drugs will need to get their medications elsewhere.

Compound versions of some weight loss drugs to be restricted

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for weight loss, as is permissible by the FDA.

Eli Lilly’s Dave Ricks takes home $114 million as obesity drugs fuel company’s fortunes

Eli Lilly’s rising fortunes tied to its weight loss and diabetes drugs led to a nine-figure payday for its top executive.

4d

Eli Lilly's first weight loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

2don MSN

Access to Compounded GLP-1s Is Drying Up. Here’s What to Know About the Copycat Weight-Loss Drugs.

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

4don MSN

Is Eli Lilly Stock a Buy?

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

4d

Amgen: Riding The MariTide Of Monthly Weight Loss

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results